For instance, the fully human IgG2 antibody Tarextumab (TRXT, OMP59R5) combined with chemotherapy has been shown to significantly reduce tumor recurrence in patient-derived SCLC xenografts, by targeting Notch2/Notch3 [148]. This evidence concerns the gene NOTCH2 and neoplasm.